Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/24982
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-03-14T08:51:40Z | - |
dc.date.available | 2022-03-14T08:51:40Z | - |
dc.date.issued | 2002 | - |
dc.identifier.citation | Egel, Ç. vd. (2002). "Inhibitory effects of ascorbic acid and folinic acid on chromosome aberrations induced by pyrimethamine in vitro". Teratogenesis Carcinogenesis and Mutagenesis, 22(5), 353-362. | tr_TR |
dc.identifier.issn | 02703211 | - |
dc.identifier.uri | https://doi.org/10.1002/tcm.10030 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1002/tcm.10030 | - |
dc.identifier.uri | http://hdl.handle.net/11452/24982 | - |
dc.description.abstract | In this study, the anticlastogenic effects of ascorbic acid and the protective effect of folinic acid against the formation of chromosomal aberrations in humans by pyrimethamine were investigated. Pyrimethamine is a folic acid antagonist used for the treatment of malaria and toxoplasmosis. In this study, 18 different healthy people, who do not drink alcohol and are non-smokers, were chosen as an experimental group; 0.025 mg/ml pyrimethamine was given to the lymphocyte culture, which had been prepared with the peripheral blood taken from this group. After that each of the following doses were given to the same culture: 20, 40, and 80 mM of ascorbic acid and 25, 50, and 100 mM of folinic acid. The results of the cytogenetic evaluation showed that the aberrations due to pyrimethamine in the chromosomes were reduced by ascorbic acid and folinic acid significantly, depending on the given dose. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley-Liss | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Anticlastogen | en_US |
dc.subject | Ascorbic acid | en_US |
dc.subject | Chromosomal aberration | en_US |
dc.subject | Folinic acid | en_US |
dc.subject | Protective effect | en_US |
dc.subject | Pyrimethamine | en_US |
dc.subject | Human-lymphocyte-cultures | en_US |
dc.subject | Sister-chromatid exchanges | en_US |
dc.subject | Vitamin-C | en_US |
dc.subject | Fragile sites | en_US |
dc.subject | V79 Cells | en_US |
dc.subject | In-vitro | en_US |
dc.subject | Genotoxicity | en_US |
dc.subject | Induction | en_US |
dc.subject | Damage | en_US |
dc.subject | Agents | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Ascorbic acid | en_US |
dc.subject.mesh | Cells, cultured | en_US |
dc.subject.mesh | Chromosome aberrations | en_US |
dc.subject.mesh | Human | en_US |
dc.subject.mesh | Dose-response relationship | en_US |
dc.subject.mesh | Folic acid antagonists | en_US |
dc.subject.mesh | Leucovorin | en_US |
dc.subject.mesh | Mitosis | en_US |
dc.subject.mesh | Pyrimethamine | en_US |
dc.subject.mesh | Cells, cultured | en_US |
dc.subject.mesh | Drug | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Mitosis | en_US |
dc.title | Inhibitory effects of ascorbic acid and folinic acid on chromosome aberrations induced by pyrimethamine in vitro | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000177779100005 | tr_TR |
dc.identifier.scopus | 2-s2.0-0036025188 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0002-3595-6286 | tr_TR |
dc.identifier.startpage | 353 | tr_TR |
dc.identifier.endpage | 362 | tr_TR |
dc.identifier.volume | 22 | tr_TR |
dc.identifier.issue | 5 | tr_TR |
dc.relation.journal | Teratogenesis Carcinogenesis and Mutagenesis | en_US |
dc.contributor.buuauthor | Egel, Çiğdem | - |
dc.contributor.buuauthor | Bilaloğlu, Rahmi | - |
dc.contributor.buuauthor | Aydemir, Nilüfer | - |
dc.contributor.researcherid | AAH-5296-2021 | tr_TR |
dc.identifier.pubmed | 12210498 | tr_TR |
dc.subject.wos | Oncology genetics & heredity | en_US |
dc.subject.wos | Toxicology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q3 (Toxicology) | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 6507862539 | tr_TR |
dc.contributor.scopusid | 6505804122 | tr_TR |
dc.contributor.scopusid | 26533892300 | tr_TR |
dc.subject.scopus | Hyperpigmentation; Vitamin B 12 Deficiency; Megaloblastic Anemia | en_US |
dc.subject.emtree | Ascorbic acid | en_US |
dc.subject.emtree | Clastogen | en_US |
dc.subject.emtree | Chromosome aberration | en_US |
dc.subject.emtree | Pyrimethamine | en_US |
dc.subject.emtree | Folic acid antagonist | en_US |
dc.subject.emtree | Folinic acid | en_US |
dc.subject.emtree | Toxoplasmosis | en_US |
dc.subject.emtree | Ascorbic acid | en_US |
dc.subject.emtree | Folic acid antagonist | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Smoking | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Alcohol consumption | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cell protection | en_US |
dc.subject.emtree | Chromosome aberration | en_US |
dc.subject.emtree | Cytogenetics | en_US |
dc.subject.emtree | Dose time effect relation | en_US |
dc.subject.emtree | Lymphocyte culture | en_US |
dc.subject.emtree | Dose calculation | en_US |
dc.subject.emtree | Dose response | en_US |
dc.subject.emtree | Evaluation | en_US |
dc.subject.emtree | Human experiment | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | Malaria | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Normal human | en_US |
dc.subject.emtree | Cell culture | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Mitosis | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.